Logo image of ALMKS.PA

MAKING SCIENCE GROUP SA (ALMKS.PA) Stock Fundamental Analysis

Europe - EPA:ALMKS - ES0105463006 - Common Stock

8.95 EUR
0 (0%)
Last: 10/31/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, ALMKS scores 2 out of 10 in our fundamental rating. ALMKS was compared to 66 industry peers in the Media industry. Both the profitability and financial health of ALMKS have multiple concerns. ALMKS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year ALMKS has reported negative net income.
ALMKS had a positive operating cash flow in the past year.
In the past 5 years ALMKS reported 4 times negative net income.
ALMKS had a positive operating cash flow in 4 of the past 5 years.
ALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

The Return On Assets of ALMKS (-1.00%) is worse than 68.85% of its industry peers.
The Return On Equity of ALMKS (-6.68%) is worse than 68.85% of its industry peers.
ALMKS's Return On Invested Capital of 7.61% is fine compared to the rest of the industry. ALMKS outperforms 73.77% of its industry peers.
Industry RankSector Rank
ROA -1%
ROE -6.68%
ROIC 7.61%
ROA(3y)-2.48%
ROA(5y)-1.44%
ROE(3y)-22.79%
ROE(5y)-9.81%
ROIC(3y)N/A
ROIC(5y)N/A
ALMKS.PA Yearly ROA, ROE, ROICALMKS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

ALMKS's Operating Margin of 1.87% is on the low side compared to the rest of the industry. ALMKS is outperformed by 60.66% of its industry peers.
ALMKS's Operating Margin has declined in the last couple of years.
The Gross Margin of ALMKS (20.49%) is worse than 86.89% of its industry peers.
ALMKS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 1.87%
PM (TTM) N/A
GM 20.49%
OM growth 3YN/A
OM growth 5Y-6.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.38%
GM growth 5Y-5.28%
ALMKS.PA Yearly Profit, Operating, Gross MarginsALMKS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ALMKS is creating some value.
The number of shares outstanding for ALMKS has been increased compared to 1 year ago.
Compared to 5 years ago, ALMKS has more shares outstanding
Compared to 1 year ago, ALMKS has an improved debt to assets ratio.
ALMKS.PA Yearly Shares OutstandingALMKS.PA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALMKS.PA Yearly Total Debt VS Total AssetsALMKS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ALMKS has an Altman-Z score of 1.75. This is a bad value and indicates that ALMKS is not financially healthy and even has some risk of bankruptcy.
ALMKS has a Altman-Z score of 1.75. This is in the better half of the industry: ALMKS outperforms 60.66% of its industry peers.
ALMKS has a debt to FCF ratio of 1126.96. This is a negative value and a sign of low solvency as ALMKS would need 1126.96 years to pay back of all of its debts.
ALMKS has a worse Debt to FCF ratio (1126.96) than 62.30% of its industry peers.
A Debt/Equity ratio of 0.47 indicates that ALMKS is not too dependend on debt financing.
ALMKS has a Debt to Equity ratio of 0.47. This is in the better half of the industry: ALMKS outperforms 62.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1126.96
Altman-Z 1.75
ROIC/WACC1.1
WACC6.9%
ALMKS.PA Yearly LT Debt VS Equity VS FCFALMKS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.75 indicates that ALMKS may have some problems paying its short term obligations.
With a Current ratio value of 0.75, ALMKS is not doing good in the industry: 80.33% of the companies in the same industry are doing better.
ALMKS has a Quick Ratio of 0.75. This is a bad value and indicates that ALMKS is not financially healthy enough and could expect problems in meeting its short term obligations.
ALMKS has a worse Quick ratio (0.73) than 73.77% of its industry peers.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.73
ALMKS.PA Yearly Current Assets VS Current LiabilitesALMKS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

6

3. Growth

3.1 Past

ALMKS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.02%, which is quite impressive.
Looking at the last year, ALMKS shows a quite strong growth in Revenue. The Revenue has grown by 16.03% in the last year.
The Revenue has been growing by 51.21% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)63.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-319.11%
Revenue 1Y (TTM)16.03%
Revenue growth 3Y35.32%
Revenue growth 5Y51.21%
Sales Q2Q%21.07%

3.2 Future

The Earnings Per Share is expected to grow by 15.62% on average over the next years. This is quite good.
The Revenue is expected to grow by 22.10% on average over the next years. This is a very strong growth
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALMKS.PA Yearly Revenue VS EstimatesALMKS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ALMKS.PA Yearly EPS VS EstimatesALMKS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

0

4. Valuation

4.1 Price/Earnings Ratio

ALMKS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 36.56, the valuation of ALMKS can be described as expensive.
ALMKS's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. ALMKS is more expensive than 65.57% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.55. ALMKS is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 36.56
ALMKS.PA Price Earnings VS Forward Price EarningsALMKS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

ALMKS's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. ALMKS is more expensive than 68.85% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ALMKS is valued a bit more expensive than the industry average as 62.30% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 1601.02
EV/EBITDA 9.68
ALMKS.PA Per share dataALMKS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

A more expensive valuation may be justified as ALMKS's earnings are expected to grow with 15.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.46%
EPS Next 3Y15.62%

0

5. Dividend

5.1 Amount

No dividends for ALMKS!.
Industry RankSector Rank
Dividend Yield N/A

MAKING SCIENCE GROUP SA

EPA:ALMKS (10/31/2025, 7:00:00 PM)

8.95

0 (0%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)07-31 2025-07-31
Earnings (Next)N/A N/A
Inst Owners3.56%
Inst Owner ChangeN/A
Ins Owners61.03%
Ins Owner ChangeN/A
Market Cap80.37M
Revenue(TTM)273.55M
Net Income(TTM)-1719600
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-64.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 36.56
P/S 0.29
P/FCF 1601.02
P/OCF 246.61
P/B 3.12
P/tB N/A
EV/EBITDA 9.68
EPS(TTM)-0.19
EYN/A
EPS(NY)0.24
Fwd EY2.74%
FCF(TTM)0.01
FCFY0.06%
OCF(TTM)0.04
OCFY0.41%
SpS30.46
BVpS2.87
TBVpS-4.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1%
ROE -6.68%
ROCE 10.35%
ROIC 7.61%
ROICexc 13.76%
ROICexgc N/A
OM 1.87%
PM (TTM) N/A
GM 20.49%
FCFM 0.02%
ROA(3y)-2.48%
ROA(5y)-1.44%
ROE(3y)-22.79%
ROE(5y)-9.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-6.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.38%
GM growth 5Y-5.28%
F-Score6
Asset Turnover1.58
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1126.96
Debt/EBITDA 1.05
Cap/Depr 4.23%
Cap/Sales 0.1%
Interest Coverage 1.14
Cash Conversion 2.8%
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.73
Altman-Z 1.75
F-Score6
WACC6.9%
ROIC/WACC1.1
Cap/Depr(3y)13.72%
Cap/Depr(5y)311.76%
Cap/Sales(3y)0.4%
Cap/Sales(5y)7.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-319.11%
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue 1Y (TTM)16.03%
Revenue growth 3Y35.32%
Revenue growth 5Y51.21%
Sales Q2Q%21.07%
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A
EBIT growth 1Y279.3%
EBIT growth 3YN/A
EBIT growth 5Y41.57%
EBIT Next Year200%
EBIT Next 3Y56.86%
EBIT Next 5YN/A
FCF growth 1Y103.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y177.63%
OCF growth 3Y-64.38%
OCF growth 5YN/A

MAKING SCIENCE GROUP SA / ALMKS.PA FAQ

What is the fundamental rating for ALMKS stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALMKS.PA.


What is the valuation status of MAKING SCIENCE GROUP SA (ALMKS.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to MAKING SCIENCE GROUP SA (ALMKS.PA). This can be considered as Overvalued.


What is the profitability of ALMKS stock?

MAKING SCIENCE GROUP SA (ALMKS.PA) has a profitability rating of 1 / 10.


What is the financial health of MAKING SCIENCE GROUP SA (ALMKS.PA) stock?

The financial health rating of MAKING SCIENCE GROUP SA (ALMKS.PA) is 2 / 10.